Despite the improved safety-profile of direct oral anticoagulants (DOACs), bleeding complications remain an important side effect of anticoagulant treatment. Although anticoagulant-specific antidotes are available, an universal anticoagulant reversal agent in case of life-threatening bleeding or emergency surgery is not yet available. Ciraparantag, a synthetic small molecule that inactivates heparins and DOAC, is a promising new reversal agent that has been investigated in phase 2 trials. In this short review we provide an overview of the preclinical and clinical evidence of ciraparantag, and compare strengths and weaknesses of ciraparantag and the currently available anticoagulant reversal strategies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.drudis.2022.07.017 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Andexanet alfa in patients with factor Xa inhibitor associated intracranial hemorrhage: the prospective observational multicenter ASTRO-DE study.
Int J Stroke
January 2025
Institute for Medical Informatics, Biometry and Epidemiology, Medical Faculty, University of Duisburg-Essen, Essen, Germany.
Background: Hematoma expansion after intracranial hemorrhage (ICH) in anticoagulated patients signifi-cantly influences clinical outcomes and mortality, emphasizing the need for effective reversal agents. Andexanet alfa is a specific reversal agent for factor Xa associated major bleeding.
Aims: The ASTRO-DE study collected real-world evidence on the effect of andexanet alfa on mitigat-ing hematoma expansion and altering prognosis in rivaroxaban- or apixaban-treated patients with ICH.
Intravenous thrombolysis for patients with acute ischemic stroke while receiving a direct oral anticoagulant: A systematic review and meta-analysis.
Pharmacotherapy
January 2025
Auburn University Harrison College of Pharmacy, Auburn, Alabama, USA.
Recent guidelines for acute ischemic stroke (AIS) indicate administration of intravenous thrombolysis (IVT) in patients receiving direct oral anticoagulants (DOAC) is not firmly established and may be harmful unless certain potential parameters are met. This systematic review and meta-analysis explores safety outcomes and other clinical parameters from the growing number of publications describing patients taking a DOAC who experience an AIS that is treated acutely with IVT alone. Embase, International Pharmaceutical Abstracts, and PubMed were searched up to January 9, 2024 for studies including adult patients taking a DOAC who experienced an AIS treated with IVT and did not undergo endovascular therapy (EVT), regardless of the use of an anticoagulation reversal agent.
View Article and Find Full Text PDFAssessing the effectiveness of a rural distribution program in reducing time to prothrombin complex concentrate administration in patients taking warfarin.
Hosp Pract (1995)
January 2025
Research Design and Biostatistics Core, Sanford Research, Sioux Falls, SD, USA.
Study Objectives: Reversal of warfarin-induced anticoagulation using prothrombin complex concentrate (PCC4) is more rapidly achieved than with traditional methods such as fresh frozen plasma (FFP). In many rural facilities the availability of both FFP and PCC4 has been limited. A tertiary hospital instituted a program to provide PCC4 to rural sites using an air transport team and pharmacy exchange.
View Article and Find Full Text PDFEffect of Pre-Transplant Renal Anticoagulation and Antiplatelet Therapy on Post-Transplant Outcomes: A Retrospective Single-Center Study.
Transplant Proc
January 2025
Department of Nephrology, La Paz University Hospital, Madrid, Spain.
The management of anticoagulation and antiplatelet therapy in stage V chronic kidney disease (CKD) patients undergoing renal transplantation remains controversial. Some centers advocate for the use of reversal agents or procoagulants preoperatively, while others suggest that transplantation can proceed safely without halting these treatments. This study aims to evaluate the incidence of hemorrhagic and thrombotic complications in the first 72 hours post-transplant in patients receiving anticoagulant or antiplatelet therapy compared to a control group without such treatments.
View Article and Find Full Text PDFThromboelastography may assess the effect of anticoagulation reversal in intracranial hemorrhage.
J Stroke Cerebrovasc Dis
January 2025
Department of Neurology, University of Iowa College of Medicine, United States; Department of Epidemiology, University of Iowa College of Public Health, United States; Department of Neurosurgery, University of Iowa College of Medicine, United States.
Article Synopsis
- Intracranial hemorrhage (ICH) is a serious risk for patients on oral anticoagulants, and there's a need for biomarkers to evaluate the effectiveness of reversal agents like activated prothrombin complex concentrate (aPCC).
- A study was conducted in an emergency department with adult patients experiencing factor Xa inhibitor-related ICH to assess changes in thromboelastography (TEG) following aPCC reversal.
- Results showed a significant decrease in TEG R-time shortly after aPCC administration, but it returned to baseline levels by 12 and 24 hours, suggesting TEG R-time could be a valuable biomarker to monitor anticoagulation effects in these patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!